Skip to content
2000
Volume 15, Issue 8
  • ISSN: 1574-888X
  • E-ISSN: 2212-3946

Abstract

Heart failure is a significant source of morbidity and mortality around the world. Recently, cell therapy has garnered much attention as a means for improving cardiac function after injury. Despite years of study, a growing list of failed efficacy trials has led many to question the translatability of preclinical work. In this review, we critically evaluate the evidence supporting the need for transplanted cells to engraft and persist in the impaired heart (the cell engraftment hypothesis). We explore how the complex interplay between cell retention, persistence and paracrine potency explains many of the recent cell treatment outcomes. Through this discussion, we outline a framework to understand how future approaches will optimize and personalize the methods, payloads and timing of cardiac cell delivery for the millions of patients worldwide suffering from heart failure.

Loading

Article metrics loading...

/content/journals/cscr/10.2174/1574888X15666200206103005
2020-11-01
2025-05-02
Loading full text...

Full text loading...

/content/journals/cscr/10.2174/1574888X15666200206103005
Loading

  • Article Type:
    Review Article
Keyword(s): cytokine; differentiation; engraftment; exosome; heart failure; Stem cell
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test